The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).
 
Akshara Singareeka Raghavendra
No Relationships to Disclose
 
Danielle Kwiatkowski
No Relationships to Disclose
 
Senthil Damodaran
Honoraria - Novartis
Research Funding - EMD Serono (Inst); Guardant Health (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Phillips Gilmore Oncology Communications
 
Nicole M. Kettner
No Relationships to Disclose
 
David Luis Ramirez
No Relationships to Disclose
 
Dan S. Gombos
Consulting or Advisory Role - Abbvie
Travel, Accommodations, Expenses - Abbvie
Other Relationship - 3T Ophthalmics; Aura Biosciences
 
Kelly Hunt
Consulting or Advisory Role - Armada Health Care; Merck
Research Funding - CairnSurgical (Inst); Endomagnetics (Inst); Lilly (Inst); Lumicell (Inst); OncoNano Inc (Inst)
 
Yu Shen
No Relationships to Disclose
 
Khandan Keyomarsi
Stock and Other Ownership Interests - pfizer
Research Funding - Tesaro (Inst)
 
Debu Tripathy
Consulting or Advisory Role - AstraZeneca; Genomic Health; GlaxoSmithKline; Novartis; OncoPep; Pfizer
Research Funding - Novartis (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis